Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 9/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25616564 | 0.84 | CHRM2 (0.46) | OPRM1CHRM1CHRM2CHRM4 | |
| SCHEMBL28908346 | 0.82 | ADORA3 (0.45) | ALDH1A1OPRM1CHRM1CHRM2CHRM4 | |
| SCHEMBL23217008 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNATNKSPARP1TNKS2 | |
| SCHEMBL29844265 | 0.78 | C5AR1 (0.36) | ALDH1A1LMNAOPRM1TNKSTNKS2 | |
| SCHEMBL23216905 | 0.78 | C5AR1 (0.36) | ALDH1A1LMNAOPRM1TNKSTNKS2 | |
| SCHEMBL18818255 | 0.74 | RPS6KA5 (0.43) | ADORA3ADORA2B | |
| SCHEMBL18289975 | 0.74 | RPS6KA5 (0.43) | ADORA3ADORA2B | |
| SCHEMBL30866992 | 0.74 | RPS6KA5 (0.43) | ADORA3ADORA2B | |
| SCHEMBL10265182 | 0.73 | CHRM1 (0.60) | OPRM1TNKSCHRM1CHRM2CHRM4 | |
| SCHEMBL29737109 | 0.71 | RXFP1 (0.34) | OPRM1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4041401-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | HCK, LYN, BTK | ALDH1A1 4815/4885LMNA 2732/4885OPRM1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.